Abstract
Introduction Collagenase Clostridium Histolyticum (CCH) has become a therapeutic alternative for
Dupuytren disease. However, its efficacy in the medium to long term is unknown. The
objective of our study is to carry out a systematic review of the studies conducted
on the subject.
Material and Methods Systematic bibliographic search. Analysis depending on the time of progression, looking
into 2 groups with the follow-up cut-off point of 1 year. Analysis of the number of
patients who reached the primary endpoint, of the mean correction in degrees, and
of the proportional correction of each joint.
Results The 50 selected clinical trials encompass a total of 4,622 patients (an average of
92.70). A total of 7,546 joints were treated with the mean being 148.15 joints per
trial (3,925 metacarpophalangeal [MCP] and 2,350 proximal interphalangeal [PIP]).
In less than one year of progression, the primary end point was reached in 48.9% of
the joints (69.77% of the MCPs and 30.14% of the PIPs), the mean correction in degrees
was 45.5 (standard deviation [SD]: 19.18) degrees; 40.8 degrees in the MCP (SD: 10.12)
and 35.6 in the PIP (SD: 13.23), and the proportional correction of the joints was
72.9% (SD: 14.43) (83.9% for MCPs [SD: 12.58] and 64.2 for the PIPs [SD: 16.35]).
In the follow-ups over 1 year, the primary end point was reached at a rate of 57.5%
(68.9% of the MCPs and 43.3% of the PIPs), the mean correction in degrees was 37.6
degrees (SD: 10.93) (37.3 degrees in the MCPs [SD: 9.98] and 23.7 in the PIPs [SD:
16.33]) and the proportional correction of the joints was 87.3% (SD: 10.96) (90.3%
for MCP [SD: 6.94] and 75% for PIP [SD: 13.54]).
Conclusions The results indicate a satisfactory response to CCH treatment maintained in the short
and medium term. The recurrence rate is uncertain given the available data.
Keywords
collagenase - clostridium histolyticum - efficacy - systematic review
